269 related articles for article (PubMed ID: 14978141)
1. Host conditioning is a primary determinant in modulating the effect of IL-7 on murine graft-versus-host disease.
Gendelman M; Hecht T; Logan B; Vodanovic-Jankovic S; Komorowski R; Drobyski WR
J Immunol; 2004 Mar; 172(5):3328-36. PubMed ID: 14978141
[TBL] [Abstract][Full Text] [Related]
2. The balance between donor T cell anergy and suppression versus lethal graft-versus-host disease is determined by host conditioning.
Gonzalez M; Quezada SA; Blazar BR; Panoskaltsis-Mortari A; Rudensky AY; Noelle RJ
J Immunol; 2002 Nov; 169(10):5581-9. PubMed ID: 12421935
[TBL] [Abstract][Full Text] [Related]
3. Importance of interleukin-7 in the development of experimental graft-versus-host disease.
Chung B; Dudl E; Toyama A; Barsky L; Weinberg KI
Biol Blood Marrow Transplant; 2008 Jan; 14(1):16-27. PubMed ID: 18158957
[TBL] [Abstract][Full Text] [Related]
4. Kinetics of in vivo elimination of suicide gene-expressing T cells affects engraftment, graft-versus-host disease, and graft-versus-leukemia after allogeneic bone marrow transplantation.
Rettig MP; Ritchey JK; Prior JL; Haug JS; Piwnica-Worms D; DiPersio JF
J Immunol; 2004 Sep; 173(6):3620-30. PubMed ID: 15356106
[TBL] [Abstract][Full Text] [Related]
5. Alloreactive memory T cells are responsible for the persistence of graft-versus-host disease.
Zhang Y; Joe G; Hexner E; Zhu J; Emerson SG
J Immunol; 2005 Mar; 174(5):3051-8. PubMed ID: 15728519
[TBL] [Abstract][Full Text] [Related]
6. Ex vivo anti-CD3 antibody-activated donor T cells have a reduced ability to cause lethal murine graft-versus-host disease but retain their ability to facilitate alloengraftment.
Drobyski WR; Majewski D; Ozker K; Hanson G
J Immunol; 1998 Sep; 161(5):2610-9. PubMed ID: 9725263
[TBL] [Abstract][Full Text] [Related]
7. Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease.
Fowler DH; Breglio J; Nagel G; Eckhaus MA; Gress RE
J Immunol; 1996 Dec; 157(11):4811-21. PubMed ID: 8943383
[TBL] [Abstract][Full Text] [Related]
8. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
[TBL] [Abstract][Full Text] [Related]
9. An absence of CCR5 on donor cells results in acceleration of acute graft-vs-host disease.
Welniak LA; Wang Z; Sun K; Kuziel W; Anver MR; Blazar BR; Murphy WJ
Exp Hematol; 2004 Mar; 32(3):318-24. PubMed ID: 15003318
[TBL] [Abstract][Full Text] [Related]
10. The identification and characteristics of IL-22-producing T cells in acute graft-versus-host disease following allogeneic bone marrow transplantation.
Zhao K; Zhao D; Huang D; Song X; Chen C; Pan B; Wu Q; Cao J; Yao Y; Zeng L; Xu K
Immunobiology; 2013 Dec; 218(12):1505-13. PubMed ID: 23816304
[TBL] [Abstract][Full Text] [Related]
11. Administration of interleukin-7 after allogeneic bone marrow transplantation improves immune reconstitution without aggravating graft-versus-host disease.
Alpdogan O; Schmaltz C; Muriglan SJ; Kappel BJ; Perales MA; Rotolo JA; Halm JA; Rich BE; van den Brink MR
Blood; 2001 Oct; 98(7):2256-65. PubMed ID: 11568014
[TBL] [Abstract][Full Text] [Related]
12. Host conditioning with total lymphoid irradiation and antithymocyte globulin prevents graft-versus-host disease: the role of CD1-reactive natural killer T cells.
Lan F; Zeng D; Higuchi M; Higgins JP; Strober S
Biol Blood Marrow Transplant; 2003 Jun; 9(6):355-63. PubMed ID: 12813443
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-10 administration decreases survival in murine recipients of major histocompatibility complex disparate donor bone marrow grafts.
Blazar BR; Taylor PA; Smith S; Vallera DA
Blood; 1995 Feb; 85(3):842-51. PubMed ID: 7833486
[TBL] [Abstract][Full Text] [Related]
14. Elimination of leukemia in the absence of lethal graft-versus-host disease after allogenic bone marrow transplantation.
Drobyski WR; Gendelman M; Vodanovic-Jankovic S; Gorski J
J Immunol; 2003 Mar; 170(6):3046-53. PubMed ID: 12626559
[TBL] [Abstract][Full Text] [Related]
15. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
[TBL] [Abstract][Full Text] [Related]
16. Donor-derived IL-15 is critical for acute allogeneic graft-versus-host disease.
Blaser BW; Roychowdhury S; Kim DJ; Schwind NR; Bhatt D; Yuan W; Kusewitt DF; Ferketich AK; Caligiuri MA; Guimond M
Blood; 2005 Jan; 105(2):894-901. PubMed ID: 15374888
[TBL] [Abstract][Full Text] [Related]
17. IL-7 drives donor T cell proliferation and can costimulate cytokine secretion after MHC-matched allogeneic bone marrow transplantation.
Levy RB; Jones M; Hamilton BL; Paupe J; Horowitz T; Riley R
J Immunol; 1995 Jan; 154(1):106-15. PubMed ID: 7995931
[TBL] [Abstract][Full Text] [Related]
18. Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets.
Johnson BD; Becker EE; Truitt RL
Biol Blood Marrow Transplant; 1999; 5(3):123-32. PubMed ID: 10392958
[TBL] [Abstract][Full Text] [Related]
19. Host T cells resist graft-versus-host disease mediated by donor leukocyte infusions.
Blazar BR; Lees CJ; Martin PJ; Noelle RJ; Kwon B; Murphy W; Taylor PA
J Immunol; 2000 Nov; 165(9):4901-9. PubMed ID: 11046015
[TBL] [Abstract][Full Text] [Related]
20. T cell subsets involved in lethal graft-versus-host disease directed to immunodominant minor histocompatibility antigens.
Berger M; Wettstein PJ; Korngold R
Transplantation; 1994 Apr; 57(7):1095-102. PubMed ID: 7909395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
